The document discusses recent advances in antithrombotic therapy. It describes the components of thrombus, types of thrombosis, and pathological conditions like stroke and myocardial infarction. Newer antithrombotic agents discussed include direct factor Xa inhibitors, tissue factor inhibitors, and platelet inhibitors that target receptors like P-selectin, GPVI collagen receptor, and ADP receptors. While these new agents show promise, conventional treatments like heparin, coumarins and aspirin remain standard of care due to side effects and costs of newer therapies. Continued research is needed to develop safer, more effective antithrombotic drugs.